Abstract
Patients with Addison’s disease are at greater risk of having reduced bone mineral density and hip fractures and are thus more likely to receive a bisphosphonate than their peers. Potent intravenous bisphosphonates could provoke an acute phase reaction. An 80-year-old female with Addison’s disease received her first infusion of zoledronic acid for osteoporosis at our outpatient clinic around noon. Despite doubling her usual afternoon hydrocortisone dose, she became feverish, nauseous, extremely weak, and hypotensive over the night. When transported to the nearest general hospital the next morning, the patient was found to have signs of hypovolemic shock and she was admitted to the ICU. Crystalloid infusion, followed by dobutamine and norepinephrine drip, had no effect. Only after her European emergency card for glucocorticoid cover was found, adrenal crisis was recognized, and she was immediately given an intravenous bolus of hydrocortisone followed by continuous hydrocortisone infusion. The patient rapidly improved and was transferred to a regular ward the next day, where hydrocortisone dose was gradually tapered. Our experience might suggest that patients with Addison’s disease should probably start their treatment with zoledronic acid in a hospital setting. Their usual oral dose of hydrocortisone should be doubled or even tripled. Careful monitoring of these patients seems to be warranted, and intravenous hydrocortisone should be given if any symptoms or signs of the imminent adrenal crisis are noted.
Similar content being viewed by others
References
Bensing S, Hulting A, Husebye E, Kämpe O, Løvås K (2016) Management of endocrine disease: epidemiology, quality of life and complications of primary adrenal insufficiency: a review. Eur J Endocrinol 175(3):107–116
Brandão Neto R, Carvalho J (2014) Diagnosis and classification of Addison’s disease (autoimmune adrenalitis). Autoimmun Rev 13(4–5):408–411
Napier C, Pearce S (2012) Autoimmune Addison’s disease. Presse Med 41(12):626–635
Husebye E, Allolio B, Arlt W, Badenhoop K, Bensing S, Betterle C et al (2016) Consensus statement on the diagnosis, treatment and follow-up of patients with primary adrenal insufficiency. J Intern Med 275(2):104–115
Allolio B (2014) Extensive expertise in endocrinology: adrenal crisis. Eur J Endocrinol 172(3):115–124
Napier C, Pearce S (2014) Current and emerging therapies for Addisonʼs disease. Curr Opin Endocrinol Diabetes Obes 21(3):147–153
Weinstein RS (2011) Clinical practice: glucocorticoid-induced bone disease. N Engl J Med 365:62–70
Björnsdottir S, Sääf M, Bensing S, Kämpe O, Michaëlsson K, Ludvigsson JF (2011) Risk of hip fracture in Addison’s disease: a population-based cohort study. J Intern Med 270:187–195
Lee P, Greenfield J (2015) What is the optimal bone-preserving strategy for patients with Addison’s disease? Clin Endocrinol 83(2):157–161
Lovas K, Gjesdal CG, Christensen M, Wolff AB, Almas B, Svartberg J, Fougner KJ, Syversen U, Bollerslev J, Falch JA, Hunt PJ, Chatterjee VKK, Husebye ES (2009) Glucocorticoid replacement therapy and pharmacogenetics in Addison’s disease: effects on bone. Eur J Endocrinol 160:993–1002
Tanvetyanon T, Stiff PJ (2006) Management of the adverse effects associated with intravenous bisphosphonates. Ann Oncol 17(6):897–907
Kennel K, Drake M (2009) Adverse effects of bisphosphonates: implications for osteoporosis management. Mayo Clin Proc 84(7):632–638
McClung M (2016) Cancel the denosumab holiday. Osteoporos Int 27(5):1677–1682
Wark JD, Bensen W, Recknor C, Ryabitseva O, Chiodo J 3rd, Mesenbrink P, de Villiers TJ (2012) Treatment with acetaminophen/paracetamol or ibuprofen alleviates post-dose symptoms related to intravenous infusion with zoledronic acid 5 mg. Osteoporos Int 23(2):503–512
Salvatori R (2005) Adrenal insufficiency. JAMA 294(19):2481–2488
Billington E, Horne A, Gamble G, Maslowski K, House M, Reid I (2017) Effect of single-dose dexamethasone on acute phase response following zoledronic acid: a randomized controlled trial. Osteoporos Int 28(6):1867–1874
Chen CH, Lu YM, Lin SY, Chen JC, Huang PJ, Huang HT, Fu YC (2013) Prevention of acute phase reaction of intravenous bisphosphonates. Osteoporos Int 24(Suppl 4):S589
Reid I, Horne A, Mihov B, Gamble G (2017) Bone loss after denosumab: only partial protection with zoledronate. Calcif Tissue Int 101(4):371–374
Freemantle N, Satram-Hoang S, Tang E, Kaur P, Macarios D, Siddhanti S, Borenstein J, Kendler D (2011) Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month randomized crossover comparison with alendronate in postmenopausal women. Osteoporos Int 23(1):317–326
Abrahamsen B, Eiken P, Eastell R (2011) Proton pump inhibitor use and the antifracture efficacy of alendronate. Arch Intern Med 171(11):998–1004
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of interest
None.
Rights and permissions
About this article
Cite this article
Smrecnik, M., Kavcic Trsinar, Z. & Kocjan, T. Adrenal crisis after first infusion of zoledronic acid: a case report. Osteoporos Int 29, 1675–1678 (2018). https://doi.org/10.1007/s00198-018-4508-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00198-018-4508-7